MEDX

[Richard]

With the acquisition of ABGX, I guess there's a lot of press about which bio will be next. MEDX seems to be on people's radar screens. I guess the story is that MEDX has some solid candidates for cancer treatments, and companies may be intrested in acquiring MEDX to complete the picture.

This stock tried to breakout not to long ago, but had no volume, so it just slumped right back down. Now it's seems to have the big volume move above resistance:

Is it all hype? Or is there some substance here?

[Richard]

Hype vs. substance is immaterial I suppose. After all, no one's ever said to me "I'm sorry sir, we can't take your money, it came from hype"...

[Richard]

Still on a steep uptrend, but starting to look rather overbought.

[la-onda]

Could Medarex be next?Monday , May 15, 2006 18:39 ET

BOSTON, May 16, 2006 (XFN via COMTEX) -- Now that Cambridge Antibody Technology Group has been snagged by AstraZeneca, and Amgen has gobbled up Abgenix, will rival Medarex be the next takeover target?

Investors appeared to think so on Monday, bidding shares of the Princeton, N.J.-based antibody developer as high as $12.13. Medarex shares finished the day up 6% at $11.64.

Cambridge Antibody Technology , also known as CAT, Medarex and Abgenix have long been considered a sort of troika in the field of therapeutic monoclonal antibodies development. And with Abgenix, and now apparently CAT, out of the running, analysts see Medarex as the next in line to be scooped up by a major drug company.
Medarex's shares have reflected this. The stock has been on a roll since December, when biotech giant Amgen announced it was buying Medarex's leading U.S. competitor, Abgenix, for $2.2 billion in cash, or $22.50 a share. That deal closed last month.
Early Monday, AstraZeneca said it planned to buy the 80% of CAT that it didn't already own for about $1.3 billion, or $24.98 a share.
"There are a dwindling number of them, and now just one major one, Medarex," said Janney Montgomery Scott analyst Brian Rye, of the monoclonal antibody developers. Janney served as co-manager of a recent offering for Medarex.
Rye added that although he did not believe Medarex management was actively seeking a deal, they could be willing to sell "if the price were right."
"I wouldn't be surprised if Medarex were next, but it would be a trickier buyout because of so partnerships it has," said Global Crown Capital analyst Kate Winkler, who does not own shares in Medarex, nor does her firm do investment banking. "You'd have to pay more money."
Possible bidders for Medarex would likely be one of their major partners. Analysts point out that AstraZeneca already had about a 20% stake in CAT before it bid. And Amgen said it was buying Abgenix to gain full control over a promising antibody the two were developing, panitumumab, for the treatment of cancer.
"Abgenix had a higher profile drug, panitumumab, but historically Medarex has been the company most chosen by Big Pharma to work with," said Winkler.

Both analysts agreed that Medarex's two biggest development partners, Pfizer and Bristol-Myers Squibb , would be the most likely contenders for Medarex.
Johnson & Johnson , which has partnered with Medarex on two Phase III-stage drug candidates, is third possibility.
According to Rye, Pfizer already holds about a 5% stake in Medarex. The two companies currently have an antibody to treat melanoma in Phase III testing and a broad technology agreement in place.
Further fanning speculation is the fact that Pfizer, the world's largest pharmaceutical company, has announced it is interested in making more acquisitions for its pipeline. In addition, last June, Pfizer announced it was forking out $1.9 billion for European biotech group Vicuron, a developer of anti-infective drugs.
"They've demonstrated that price is not an obstacle," said Rye, adding he would expect Medarex to garner a price at least as high as Abgenix's, given the strength of its technology.
A second contender could be Bristol-Myers Squibb, which Rye said has partnered with Medarex on another late-stage drug for melanoma. If that drug makes it to market, Bristol-Myers would have to split profits 55% to 45% with Medarex, a prospect that may prompt the Blue Chip to buy the biotech group.
Rye said Bristol-Myers would likely make such a move Phase III data on the drug is released. That data is expected some time in 2007, he said.

&

MEDX: Short Interest DN 5.8% to 9.5M in May 2006
Wednesday, May 24, 2006 16:20 ET

According to new short interest data from NASDAQ, short interest for Medarex Inc (NasdaqNM: MEDX) DECREASED 5.8% to 9,471,996 shares for the month ended mid-May, 2006.

SYMBOL             APRIL             MAY          CHANGE       %CHANGE     DAYS/COVER
--------   -------------   -------------   -------------  ------------  ----------
MEDX          10,056,713       9,471,996        -584,717        -5.81%           8

Based on MEDX's 20-day average daily share volume of 1,259,500, it would require approximately 8 day(s) of buying to cover this short interest.

chart update:

[la-onda]

bought a few @ 10.15 

nice pipeline & MACD crossing soon

[la-onda]

any feedback from you ?? 

updated chart:

[sebfr]

A bearish strategy for a possible 33% profit 

SELL at 10.68
Target at 8.70
stop loss at 11.18

Technical analysis :
1. Candelstick : piercing line
2. MA200 as support and price crosses under MA200
3. Chart : resistance + gap of the end of 2005
4. Retracement : between 50% and 61.8%
5. Bollinger bands : close under upper bands # yesterday's
6. Oscillator (RSI + %D) : Overbought

Good trades

[la-onda]

nice and steady gains for the last weeks 

headlines:
http://finance.yahoo.com/q/h?s=MEDX

cheers
O.

[mexirafa]

Could MEDX retest YTD highs??

[la-onda]

update:
Medarex initiated with "buy"

Friday, March 16, 2007 3:09:35 AM ET
A.G. Edwards & Sons

NEW YORK, March 16 (newratings.com) - Analysts at AG Edwards initiate coverage of Medarex Inc (MEDX.NAS) with a "buy" rating. The target price is set to $16. In a research note dated March 14 and published this morning, the analysts mention that the company's pipeline is one of the broadest in the biotech industry. Medarex would receive royalties from BMY and PFE for ipilimumab and ticilimumab, respectively, going forward, the analysts say. The company would also receive royalties on its Phase III autoimmune candidates going ahead. The company has sufficient cash to fund its operations until 2011, AG Edwards adds.

[la-onda]

update:
MEDX: Short Interest UP 5.9% to 29.2M in Aug 2007
Friday , August 24, 2007 16:19ET

According to new short interest data from NASDAQ, short interest for Medarex Inc (NasdaqNM: MEDX) INCREASED 5.9% to 29,211,635 shares for the month ended mid-August, 2007.
Based on MEDX's 20-day average daily share volume of 3,997,805, it would require approximately 8 day(s) of buying to cover this short interest.

&

Small-Cap Spotlight: Medarex
Page 3

Trading Center

Fisher Investments   
Global Forex

TD AMERITRADE   
Fidelity Investments

Charles Schwab   
Zecco.com

In addition, Medarex has 25 other product candidates in phase I or II clinical testing. This pipeline not only creates somewhat of a safety net for investors if its main product stumbles, but also provides additional long-term catalysts that could push the stock higher in the months and years after the MDX 010 story plays out.

Aside from the strong pipeline, Medarex is in better financial condition than most biotech plays out there. The company sports $3.37 in cash per share on its balance sheet -- about three times its total debt. Second-quarter results announced on July 31 came in slightly better than expected as Medarex reported a 32-cent loss in GAAP earnings vs. Street estimates for a 35-cent loss. Analysts at investment bank AG Edwards noted lower-than-expected spending in R&D and general and administrative expenses as factors in the earnings beat.

Lastly, one of my required characteristics before labeling a stock as a potential big winner is a high short position. Based on data from Nasdaq.com, Medarex has about 20% to 25% of its total float shorted. While some of this is likely the result of hedging by some large investors who own shares, there are still more than enough shorts in the stock to generate a nice gap up on any positive developments for Medarex.
For those looking for potential big returns on a speculative small-cap, Medarex is a smart pick for the riskier portion of your portfolio.